Summary
The product CIALIS, manufactured by Unique Pharma, underwent independent testing to confirm its authenticity and potency. The sample, identified by batch number UN65521, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Tadalafil, with concentrations of 18.98 mg and 19.17 mg, slightly below the labeled claim of 20 mg by 5.1% and 4.15%, respectively.
The testing process began on 06 February 2023, with the sample received on 15 February 2023, and analysis completed on 21 February 2023. While the results confirm relatively accurate dosing, it’s important to critically evaluate reseller-submitted samples to ensure reliability. Resellers may selectively submit high-quality batches, raising questions about product consistency across the market. Independent third-party testing remains vital for comprehensive validation. This report is intended as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: CIALIS
- Active Ingredient: Tadalafil
- Batch Number: UN65521
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #27624
- Testing Ordered: 06 February 2023
- Sample Received: 15 February 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 20 mg (as stated on the label)
- Measured Concentration: 18.98 mg; 19.17 mg
- Accuracy: 94.9% and 95.85% (-5.1% and -4.15% below label claim)
- Variance: -1.02
Verification Details
- Verification URL: https://janoshik.com/tests/27624_QLY8MV5DVNSL
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis confirms the relative accuracy of the tested product but warrants scrutiny due to its submission and funding by the reseller Opitropin.EU. Resellers may selectively choose optimal batches for testing, which might not reflect overall market consistency. While Janoshik Analytical is recognized for its transparency and rigorous protocols, additional third-party testing across multiple batches would help validate the findings comprehensively.
Conclusion
The analysis indicates that CIALIS by Unique Pharma is slightly underdosed, with measured concentrations of 18.98 mg and 19.17 mg, reflecting relatively strong quality control for this batch. However, further testing across different batches is crucial for consistent assurance. This report aims to support educational and harm reduction efforts, assisting consumers in making informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may introduce biases; however, it still provides valuable insights when critically evaluated alongside independent third-party results. Readers are encouraged to use this information responsibly.
